Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Clin Cancer Res. 2020 Jan 10;26(8):1812–1819. doi: 10.1158/1078-0432.CCR-19-3443

Table 1:

Patient Characteristics

Characteristics No. of patients (%)
Total no. of evaluable patients 32
Age (median, range) 65.5(40,83)
Sex
  Male 14 (44%)
  Female 18 (56%)
Race
  White 30 (100%)
  Unknown 2
Ethnicity
  Hispanic 2 (7%)
  Non-Hispanic 28 (93%)
  Unknown 2
ECOG PS
  0 6 (19%)
  1 26 (81%)
No. of prior therapies
  1 6 (19%)
  2 4 (12%)
  3 4 (12%)
  >3 18 (56%)
Weight loss in previous 6 months
  < 5% 26 (81%)
  5 to < 10% 4 (12%)
  10 to < 20% 3 (6%)
Tumor Histology
Gastrointestinal 8 (25%)
 Adenocarcinoma of colon 6
 Adenocarcinoma of rectum 1
 Intrahepatic cholangiocarcinoma 1
Gynecologic 4 (12%)
 Serous adenocarcinoma of ovary 1
 Malignant mixed Mullerian tumor of uterus 1
 Endometrioid endometrial adenocarcinoma 1
 Melanoma of vulva 1
Breast (ductal carcinoma) 1 (3%)
Lung adenocarcinoma 9 (28%)
 Adenocarcinoma 6
 Adenosquamous carcinoma 1
 Hepatoid adenocarcinoma 1
 Sarcomatoid adenocarcinoma 1
Genitourinary 5 (16%)
 Prostate adenocarcinoma 1
 Prostate adenocarcinoma with neuroendocrine differentiation 3
 Osteosarcoma of the renal pelvis 1
Lymphoma 2 (6%)
 Cutaneous T-cell anaplastic large cell lymphoma 1
 Diffuse large B-cell lymphoma 1
Spindle cell component of parotid epithelial- myoepithelial carcinoma 1
Adenocarcinoma of unknown primary site 2 (6%)